Shyeilla V. Dhuria - Concepedia

Author

Shyeilla V. Dhuria

Novartis (Switzerland)

Also Known As

S Dhuria, S. Dhuria, Shyeilla Dhuria, Shyeilla V Dhuria, Shyeilla V. Dhuria

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Massachusetts General Hospital Sarah Cannon Tennessee Oncology

About

Shyeilla V. Dhuria is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	269
2	Health Sciences	1	1	19
3	Public Health	1	1	19
4	Biochemistry	1	1	23
5	Cell Biology	1	1	23

Shyeilla V. Dhuria

Publications

851

Citations

H-Index

Page 1

	Year	Citations
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors Jeffrey R. Infante, E. Claire Dees, Anthony J. Olszanski, Journal of Clinical Oncology	2014	205
Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system Shyeilla V. Dhuria, Leah R. Hanson, William H. Frey Journal of Pharmaceutical Sciences NeuropeptidesMedicineNeuropeptide ReceptorNeuropharmacologyExperimental Pharmacology	2008	133
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study Giuseppe Curigliano, P. Gómez Pardo, Funda Meric‐Bernstam, The Breast	2016	132
Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System Shyeilla V. Dhuria, Leah R. Hanson, William H. Frey Journal of Pharmacology and Experimental Therapeutics	2008	98
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: <i>In Silico</i> and Clinical Evaluations Tanay S. Samant, Shyeilla V. Dhuria, Yasong Lu, Clinical Pharmacology & Therapeutics	2017	77
Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling Tanay S. Samant, Felix Huth, Kenichi Umehara, Clinical Pharmacology & Therapeutics	2020	41
Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis. Dejan Juric, Pamela N. Münster, Mario Campone, Journal of Clinical Oncology Breast OncologyPathologyPharmacotherapyTumor BiologyPre-clinical Pharmacology	2016	32
A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma Andrew Spencer, Aaron S. Rosenberg, Andrzej Jakubowiak, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyAmg 176MedicineImmunologyImmune Checkpoint Inhibitor	2019	29
Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer Jeffrey R. Infante, E. Claire Dees, Howard A. Burris, Cancer Research ApoptosisImmunologyAbstract 2775PathologyCell Death	2010	25
Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects Shyeilla V. Dhuria, Heidi J. Einolf, James B. Mangold, The Journal of Clinical Pharmacology Healthy SubjectsMidazolam CmaxApoptosisTime‐dependent InhibitionCell Death	2013	23

Page 1